Previous close | 2.1300 |
Open | 2.1300 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 23.00 |
Expiry date | 2024-06-21 |
Day's range | 2.1300 - 2.1300 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Exelixis reports robust financial performance and outlines key strategies in oncology asset development and commercial expansion.
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revenue Falls Short, EPS Beats Estimates Despite Restructuring Costs